End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
33.47 CNY | +2.04% | +4.20% | +11.98% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 61% by 2026.
- The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
- The company has a low valuation given the cash flows generated by its activity.
- Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+11.98% | 2.7B | C+ | ||
-0.73% | 3.42B | D- | ||
-23.44% | 3.13B | D | ||
+7.98% | 2.74B | - | ||
-9.90% | 1.78B | - | ||
+11.26% | 1.42B | - | - | |
-20.03% | 976M | - | ||
-37.98% | 709M | - | - | |
-0.53% | 456M | - | D+ | |
+5.58% | 407M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 603883 Stock
- Ratings LBX Pharmacy Chain